Mosunetuzumab and the Emerging Role of T-Cell-Engaging Therapy in Follicular Lymphoma

References

• Smith A , CrouchS, LaxSet al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br. J. Cancer112(9), 1575–1584 (2015).
   PubMed Web of Science ®Google Scholar
• Teras LR , DeSantisCE, CerhanJR, MortonLM, JemalA, FlowersCR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin.66(6), 443–459 (2016).
   PubMed Web of Science ®Google Scholar
• Dinnessen MAW , MaasCCHM, ToninoSHet al. Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era. Leukemia36(5), 1416–1420 (2022).
   PubMed Web of Science ®Google Scholar
• Dinnessen MAW , vander Poel MWM, ToninoSHet al. Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989–2016. Leukemia35(6), 1683–1695 (2021).
   PubMed Web of Science ®Google Scholar
• Sarkozy C , MaurerMJ, LinkBKet al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US Cohorts. J. Clin. Oncol.37(2), 144–152 (2019).
   PubMed Web of Science ®Google Scholar
• Casulo C , ByrtekM, DawsonKLet al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J. Clin. Oncol.33(23), 2516–2522 (2015).
   PubMed Web of Science ®Google Scholar
• Alonso-Álvarez S , ManniM, MontotoSet al. Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. Eur. J. Cancer157, 132–139 (2021).
   PubMed Web of Science ®Google Scholar
• Link BK , DayB, ZhouXet al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br. J. Haematol.184(4), 660–663 (2019).
   PubMed Web of Science ®Google Scholar
• Batlevi CL , ShaF, AlperovichAet al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J.10(7), 74 (2020).
   PubMed Web of Science ®Google Scholar
• Leonard JP , TrnenyM, IzutsuKet al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J. Clin. Oncol.37(14), 1188–1199 (2019).
   PubMed Web of Science ®Google Scholar
• Morschhauser F , TillyH, ChaidosAet al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol.21(11), 1433–1442 (2020).
   PubMed Web of Science ®Google Scholar
• Gopal AK , KahlBS, de VosSet al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med.370(11), 1008–1018 (2014).
   PubMed Web of Science ®Google Scholar
• Fowler NH , DickinsonM, DreylingMet al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med.28(2), 325–332 (2022).
   PubMed Web of Science ®Google Scholar
• Witzig TE , WhiteCA, WisemanGAet al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.17(12), 3793–3803 (1999).
   PubMed Web of Science ®Google Scholar
• Jacobson CA , ChavezJC, SehgalARet al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol.23(1), 91–103 (2022).
   PubMed Web of Science ®Google Scholar
• Budde LE , SehnLH, MatasarMet al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol.23(8), 1055–1065 (2022).
   PubMed Web of Science ®Google Scholar
• Budde LE , AssoulineS, SehnLHet al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J. Clin. Oncol.40(5), 481–491 (2022).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Lunsumio (2022). www.ema.europa.eu/en/medicines/human/EPAR/lunsumio
   Google Scholar
• Carvalho T . FDA approves Genentech’s bispecific antibody for lymphoma. Nat. Med.29(3), 507–508 (2023).
   PubMed Web of Science ®Google Scholar
• Brice P , BastionY, LepageEet al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe D’Etude des Lymphomes Folliculaires. J. Clin. Oncol.15(3), 1110–1117 (1997).
   PubMed Web of Science ®Google Scholar
• Lo AC , CampbellBA, PicklesTet al. Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. Blood136(8), 1006–1010 (2020).
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA , LiS, NeubergDet al. Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.64(3), 928–934 (2006).
   PubMed Web of Science ®Google Scholar
• Northend M , WilsonW, Clifton-HadleyLet al. Long term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy. Blood140(Suppl. 1), 1456–1458 (2022).
   Google Scholar
• Marcus R , DaviesA, AndoKet al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med.377(14), 1331–1344 (2017).
   PubMed Web of Science ®Google Scholar
• Flinn IW , vander Jagt R, KahlBet al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J. Clin. Oncol.37(12), 984–991 (2019).
   PubMed Web of Science ®Google Scholar
• Bachy E , SeymourJF, FeugierPet al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J. Clin. Oncol.37(31), 2815–2824 (2019).
   PubMed Web of Science ®Google Scholar
• Ramsay AG , ClearAJ, KellyGet al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood114(21), 4713–4720 (2009).
   PubMed Web of Science ®Google Scholar
• Morschhauser F , FowlerNH, FeugierPet al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N. Engl. J. Med.379(10), 934–947 (2018).
   PubMed Web of Science ®Google Scholar
• Robinson KS , WilliamsME, vander Jagt RHet al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J. Clin. Oncol.26(27), 4473–4479 (2008).
   PubMed Web of Science ®Google Scholar
• Sehn LH , ChuaN, MayerJet al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol.17(8), 1081–1093 (2016).
   PubMed Web of Science ®Google Scholar
• Cheson BD , ChuaN, MayerJet al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J. Clin. Oncol.36(22), 2259–2266 (2018).
   PubMed Web of Science ®Google Scholar
• Klyuchnikov E , BacherU, WooAhn Ket al. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant.51(1), 58–66 (2016).
   PubMed Web of Science ®Google Scholar
• Jurinovic V , MetznerB, PfreundschuhMet al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol. Blood Marrow Transplant.24(6), 1172–1179 (2018).
   PubMed Web of Science ®Google Scholar
• Smith SM , GodfreyJ, AhnKWet al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer124(12), 2541–2551 (2018).
   PubMed Web of Science ®Google Scholar
• Klyuchnikov E , BacherU, KrögerNMet al. Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. Biol. Blood Marrow Transplant.21(12), 2091–2099 (2015).
   PubMed Web of Science ®Google Scholar
• Dreyling M , GhielminiM, RuleSet al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.32(3), 298–308 (2021).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . B-cell lymphomas (version 2.2023) (2023). www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• Gordon LI , WitzigT, MolinaAet al. Yttrium 90–labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma5(2), 98–101 (2004).
   PubMedGoogle Scholar
• Witzig TE , GordonLI, CabanillasFet al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.20(10), 2453–2463 (2002).
   PubMed Web of Science ®Google Scholar
• Morschhauser F , RadfordJ, Van HoofAet al. 90 Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J. Clin. Oncol.31(16), 1977–1983 (2013).
   PubMed Web of Science ®Google Scholar
• Morschhauser F , RadfordJ, Van HoofAet al. Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol.26(32), 5156–5164 (2008).
   PubMed Web of Science ®Google Scholar
• Morschhauser F , TillyH, ChaidosAet al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol.21(11), 1433–1442 (2020).
   PubMed Web of Science ®Google Scholar
• Dreyling M , SantoroA, MollicaLet al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am. J. Hematol.95(4), 362–371 (2020).
   PubMed Web of Science ®Google Scholar
• Dreyling M , SantoroA, MollicaLet al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J. Clin. Oncol.35(35), 3898–3905 (2017).
   PubMed Web of Science ®Google Scholar
• Goldsmith SJ . Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin. Nucl. Med.40(2), 122–135 (2010).
   PubMed Web of Science ®Google Scholar
• Prasad V . The withdrawal of drugs for commercial reasons. JAMA Intern. Med.174(12), 1887 (2014).
   PubMed Web of Science ®Google Scholar
• Acrotech Biopharma LLC . Zevalin FDA prescribing information. https://zevalin.com/wp-content/uploads/2019/04/PI-ZEVALIN-092019.pdf
   Google Scholar
• European Medicines Agency . Zevalin Product Information. www.ema.europa.eu/en/documents/product-information/zevalin-epar-product-information_en.pdf
   Google Scholar
• Hohloch K , Windemuth-KieselbachC, KolzJet al. Radioimmunotherapy (RIT) for follicular lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the International RIT-Registry. Br. J. Haematol.184(6), 949–956 (2019).
   PubMed Web of Science ®Google Scholar
• Reddy N , Hernandez-IlizaliturriFJ, DeebGet al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol.140(1), 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Leonard JP , TrnenyM, OffnerFet al. Five-year results and overall survival update from the phase 3 randomized study AUGMENT: lenalidomide plus rituximab (R2) vs rituximab plus placebo patients with relapsed/refractory indolent non-Hodgkin lymphoma. Blood140(Suppl. 1), 561–563 (2022).
   Google Scholar
• Sehn LH , ScholzCW, LuminariSet al. A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL). J. Clin. Oncol.39(Suppl. 15), TPS7568–TPS7568 (2021).
   Web of Science ®Google Scholar
• Gopal AK , SchusterSJ, FowlerNHet al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J. Clin. Oncol.36(23), 2405–2412 (2018).
   PubMed Web of Science ®Google Scholar
• Bartlett NL , CostelloBA, LaPlantBRet al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood131(2), 182–190 (2018).
   PubMed Web of Science ®Google Scholar
• Zinzani PL , MayerJ, AuerRet al. Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial. J. Clin. Oncol.40(Suppl. 16), 7510–7510 (2022).
   Web of Science ®Google Scholar
• Phillips T , ChanH, TamCSet al. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv.6(11), 3472–3479 (2022).
   PubMed Web of Science ®Google Scholar
• Baracho G , MileticA, OmoriS, CatoM, RickertR. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr. Opin. Immunol.23(2), 178–183 (2011).
   PubMed Web of Science ®Google Scholar
• Vivanco I , SawyersCL. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat. Rev. Cancer2(7), 489–501 (2002).
   PubMed Web of Science ®Google Scholar
• Davis RE , NgoVN, LenzGet al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature463(7277), 88–92 (2010).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . FDA Introductory Comments: Oncologic Drugs Advisory Committee Meeting, 21 April 2022 (2022). www.fda.gov/media/157837/download
   Google Scholar
• Fowler NH , SamaniegoF, JurczakWet al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J. Clin. Oncol.39(15), 1609–1618 (2021).
   PubMed Web of Science ®Google Scholar
• Flinn IW , KahlBS, LeonardJPet al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood123(22), 3406–3413 (2014).
   PubMed Web of Science ®Google Scholar
• Flinn IW , MillerCB, ArdeshnaKMet al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J. Clin. Oncol.37(11), 912–922 (2019).
   PubMed Web of Science ®Google Scholar
• Skanland SS , BrownJR. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?Haematologica108(1), 9–21 (2022).
   Web of Science ®Google Scholar
• Vorobyev VI , YoonDH, KaźmierczakMet al. TEMPO: a phase 2, randomized, open-label, 2-arm study comparing 2 intermittent dosing schedules of duvelisib in subjects with indolent non Hodgkin lymphoma (iNHL). Blood138(Suppl. 1), 3545–3545 (2021).
   Google Scholar
• Zelenetz AD , SoumeraiJD, JagadeeshDet al. Preliminary safety and efficacy results with an intermittent schedule of the PI3kδ inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies. Blood132(Suppl. 1), 2893–2893 (2018).
   Google Scholar
• Pagel JM , ReddyN, JagadeeshDet al. Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24). J. Clin. Oncol.39(Suppl. 15), 7550–7550 (2021).
   Web of Science ®Google Scholar
• Béguelin W , PopovicR, TeaterMet al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell23(5), 677–692 (2013).
   PubMed Web of Science ®Google Scholar
• Morin RD , ArthurSE, AssoulineS. Treating lymphoma is now a bit EZ-er. Blood Adv.5(8), 2256–2263 (2021).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Tazemetostat prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf
   Google Scholar
• Sermer D , BrentjensR. CAR T-cell therapy: full speed ahead. Hematol. Oncol.37(Suppl. 1), 95–100 (2019).
   PubMed Web of Science ®Google Scholar
• Staerz UD , KanagawaO, BevanMJ. Hybrid antibodies can target sites for attack by T cells. Nature314(6012), 628–631 (1985).
   PubMed Web of Science ®Google Scholar
• Sanford M . Blinatumomab: first global approval. Drugs75(3), 321–327 (2015).
   PubMed Web of Science ®Google Scholar
• Hutchings M , MousR, ClausenMRet al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet398(10306), 1157–1169 (2021).
   PubMed Web of Science ®Google Scholar
• Hutchings M , Carlo-StellaC, BachyEet al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood136(Suppl. 1), 46–48 (2020).
   Google Scholar
• Hutchings M , MorschhauserF, IacoboniGet al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol.39(18), 1959–1970 (2021).
   PubMed Web of Science ®Google Scholar
• Bannerji R , ArnasonJE, AdvaniRHet al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol.9(5), e327–e339 (2022).
   PubMed Web of Science ®Google Scholar
• Sun LL , EllermanD, MathieuMet al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci. Transl. Med.7(287), 287ra70 (2015).
   PubMed Web of Science ®Google Scholar
• Hernandez G , HuwL-Y, BelousovAet al. Pharmacodynamic effects and immune correlates of response to the CD20/CD3 bispecific antibody mosunetuzumab in relapsed or refractory non-Hodgkin lymphoma. Blood134(Suppl. 1), 1585–1585 (2019).
   PubMedGoogle Scholar
• Schuster SJ , HuwL-Y, BolenCRet al. Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas. J. Clin. Oncol.40(Suppl. 16), 7526–7526 (2022).
   Web of Science ®Google Scholar
• Bartlett NL , GiriP, BuddeLEet al. Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): initial results from a phase I/II study. Blood138(Suppl. 1), 3573–3573 (2021).
   Google Scholar
• Bartlett NL , SehnLH, AssoulineSEet al. Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). J. Clin. Oncol.37(Suppl. 15), 7518–7518 (2019).
   Web of Science ®Google Scholar
• Budde EL , BartlettNL, GiriPet al. Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphomas (B-NHLs): updated results from a phase I/II study. Presented at: 64th American Society of Hematology Annual Meeting and Exposition.New Orleans, LA, USA, 10 December 2022.
   Google Scholar
• Matasar MJ , CheahCY, YoonDHet al. Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts. Blood136(Suppl. 1), 45–46 (2020).
   Google Scholar
• Bartlett NL , SehnLH, MatasarMJet al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal phase II study. Blood140(Suppl. 1), 1467–1470 (2022).
   Google Scholar
• Matasar M , BartlettNL, SehnLHet al. P1126: Mosunetuzumab is efficacious and well tolerated in patients aged <65 and ≥65 years with relapsed/refractory follicular lymphoma and ≥2 prior therapies: subgroup analysis of a pivotal phase II study. Hemasphere6, 1016–1017 (2022).
   Google Scholar
• Winkler U , JensenM, ManzkeO, SchulzH, DiehlV, EngertA. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood94(7), 2217–2224 (1999).
   PubMed Web of Science ®Google Scholar
• Wing MG , MoreauT, GreenwoodJet al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest.98(12), 2819–2826 (1996).
   PubMed Web of Science ®Google Scholar
• Neelapu SS , LockeFL, BartlettNLet al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med.377(26), 2531–2544 (2017).
   PubMed Web of Science ®Google Scholar
• Gökbuget N , DombretH, BonifacioMet al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood131(14), 1522–1531 (2018).
   PubMed Web of Science ®Google Scholar
• Lee DW , SantomassoBD, LockeFLet al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant.25(4), 625–638 (2019).
   PubMed Web of Science ®Google Scholar
• Norelli M , CamisaB, BarbieraGet al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med.24(6), 739–748 (2018).
   PubMed Web of Science ®Google Scholar
• Leclercq G , ServeraLA, DanilinSet al. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology11(1), 2039432 (2022).
   PubMed Web of Science ®Google Scholar
• Kantarjian H , SteinA, GökbugetNet al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med.376(9), 836–847 (2017).
   PubMed Web of Science ®Google Scholar
• Stein AS , SchillerG, BenjaminRet al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann. Hematol.98(1), 159–167 (2019).
   PubMed Web of Science ®Google Scholar
• Gust J , HayKA, HanafiL-Aet al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov.7(12), 1404–1419 (2017).
   PubMed Web of Science ®Google Scholar
• Santomasso BD , ParkJH, SalloumDet al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov.8(8), 958–971 (2018).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Orphan drug designations and approvals – mosunetuzumab. www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=663418
   Google Scholar
• Nastoupil LJ , MorschhauserF, ScholzCWet al. CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥1 line of systemic therapy. J. Clin. Oncol.40(Suppl. 16), TPS7588–TPS7588 (2022).
   Web of Science ®Google Scholar
• Morschhauser F , BishtonM, EyreTAet al. Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed/refractory follicular lymphoma: initial results from a phase Ib study. Blood138(Suppl. 1), 129–129 (2021).
   Google Scholar
• Potnis KC , DiM, IsufiIet al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv.7(5), 801–810 (2023).
   PubMed Web of Science ®Google Scholar
• Liu Q , FayadL, CabanillasFet al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center. J. Clin. Oncol.24(10), 1582–1589 (2006).
   PubMed Web of Science ®Google Scholar
• Templeton AJ , BoothCM, TannockIF. Informing patients about expected outcomes: the efficacy–effectiveness gap. J. Clin. Oncol.38(15), 1651–1654 (2020).
   PubMed Web of Science ®Google Scholar
• Liang F , WuZ, MoMet al. Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting. Eur. J. Cancer121, 19–28 (2019).
   PubMed Web of Science ®Google Scholar